阿托伐他汀联合曲美他嗪对冠状动脉粥样硬化性心脏病患者心功能以及炎性因子的影响
|
摘要
目的探讨阿托伐他汀联合曲美他嗪对冠状动脉粥样硬化性心脏病患者炎性因子水平及心功能的影响。方法 80例冠状动脉粥样硬化性心脏病患者,随机分为试验组和对照组,每组40例。对照组患者采取曲美他嗪进行治疗,试验组患者在对照组基础上采取阿托伐他汀进行治疗。比较两组患者治疗后心功能、炎性因子水平。结果治疗后,试验组患者左室射血分数(LVEF)为(59.23±6.17)%,高于对照组的(49.46±4.22)%,差异具有统计学意义(P<0.05);试验组患者N末端脑钠肽前体(NT-proBNP)、超敏C反应蛋白(hs-CRP)、纤维蛋白原(Fg)水平分别为(187.51±32.55)pg/ml、(1.99±0.82)mg/L、(3.61±0.57)g/L,均低于对照组的(293.2±28.22)pg/ml、(2.43±0.95)mg/L、(4.43±0.51)g/L,差异均具有统计学意义(P<0.05)。结论对冠状动脉粥样硬化性心脏病患者使用阿托伐他汀联合曲美他嗪进行治疗,可以明显改善患者的炎性因子水平及心功能,值得在临床推广。
Objective To discuss the effect of atorvastatin combined with trimetazidine on cardiac function and inflammatory factors in patients with coronary atherosclerotic heart disease. Methods A total of 80 patients with coronary atherosclerotic heart disease were randomly divided into experimental group and control group, with 40 cases in each group. The control group was treated with trimetazidine, and the experimental group was treated with atorvastatin on the basis of the control group. The cardiac function and inflammatory factors after treatment in two groups was compared. Results After treatment, the experimental group had higher left ventricular ejection fraction(LVEF) as(59.23±6.17)% than(49.46±4.22)% in the control group, and the difference was statistically significant(P<0.05). The experimental group had lower N-terminal brain natriuretic peptide precursor(NT-proBNP), hypersensitive C-reactive protein(hs-CRP), fibrinogen(Fg) respectively as(187.51±32.55) pg/ml,(1.99±0.82) mg/L and(3.61±0.57) g/L than(293.2±28.22) pg/ml,(2.43±0.95) mg/L and(4.43±0.51) g/L in the control group, and their difference was statistically significant(P<0.05). Conclusion Combinationof atorvastatin and trimetazidine can significantly improve the level of inflammatory factors and cardiac function in patients with coronary atherosclerotic heart disease, and it is worthy of clinical promotion.
Objective To discuss the effect of atorvastatin combined with trimetazidine on cardiac function and inflammatory factors in patients with coronary atherosclerotic heart disease. Methods A total of 80 patients with coronary atherosclerotic heart disease were randomly divided into experimental group and control group, with 40 cases in each group. The control group was treated with trimetazidine, and the experimental group was treated with atorvastatin on the basis of the control group. The cardiac function and inflammatory factors after treatment in two groups was compared. Results After treatment, the experimental group had higher left ventricular ejection fraction(LVEF) as(59.23±6.17)% than(49.46±4.22)% in the control group, and the difference was statistically significant(P<0.05). The experimental group had lower N-terminal brain natriuretic peptide precursor(NT-proBNP), hypersensitive C-reactive protein(hs-CRP), fibrinogen(Fg) respectively as(187.51±32.55) pg/ml,(1.99±0.82) mg/L and(3.61±0.57) g/L than(293.2±28.22) pg/ml,(2.43±0.95) mg/L and(4.43±0.51) g/L in the control group, and their difference was statistically significant(P<0.05). Conclusion Combinationof atorvastatin and trimetazidine can significantly improve the level of inflammatory factors and cardiac function in patients with coronary atherosclerotic heart disease, and it is worthy of clinical promotion.
引文
[1]陈涵,王江友,尚小珂,等.阿托伐他汀联合曲美他嗪对不稳定型心绞痛患者经皮冠状动脉介入治疗围术期心肌损伤及炎性因子的影响.中国介入心脏病学杂志, 2014, 22(11):689-692.
[2]杨琴. 80例冠心病患者采用阿托伐他汀联合曲美他嗪治疗的临床对比研究.海峡药学, 2015, 27(9):148-149.
[3]田磊.阿托伐他汀与曲美他嗪联合治疗对冠心病患者心功能、炎症因子和内皮功能的影响.海南医学院学报, 2016, 22(14):1489-1492.
[4]王立华,从振锋.阿托伐他汀联合曲美他嗪对冠心病患者的心功能、炎性因子及血管内皮功能的影响.中国合理用药探索,2018, 15(8):17-20.
[5]李新芳,侯晓清.阿托伐他汀与曲美他嗪合用治疗冠状动脉粥样硬化性心脏病研究进展.武警医学, 2010, 21(9):737-740.
[6]王新梅,栗晓莺.阿托伐他汀与曲美他嗪联合治疗对冠心病患者心功能的影响.国际医药卫生导报, 2015, 21(6):819-821.
[7]赵建.阿托伐他汀联合曲美他嗪治疗冠状动脉粥样硬化性心脏病患者的临床效果.中国药物经济学, 2016(2):45-47.
[8]马生胜.探讨阿托伐他汀联合曲美他嗪治疗冠状动脉粥样硬化性心脏病临床疗效.中西医结合心血管病电子杂志, 2014(6):76.
[2]杨琴. 80例冠心病患者采用阿托伐他汀联合曲美他嗪治疗的临床对比研究.海峡药学, 2015, 27(9):148-149.
[3]田磊.阿托伐他汀与曲美他嗪联合治疗对冠心病患者心功能、炎症因子和内皮功能的影响.海南医学院学报, 2016, 22(14):1489-1492.
[4]王立华,从振锋.阿托伐他汀联合曲美他嗪对冠心病患者的心功能、炎性因子及血管内皮功能的影响.中国合理用药探索,2018, 15(8):17-20.
[5]李新芳,侯晓清.阿托伐他汀与曲美他嗪合用治疗冠状动脉粥样硬化性心脏病研究进展.武警医学, 2010, 21(9):737-740.
[6]王新梅,栗晓莺.阿托伐他汀与曲美他嗪联合治疗对冠心病患者心功能的影响.国际医药卫生导报, 2015, 21(6):819-821.
[7]赵建.阿托伐他汀联合曲美他嗪治疗冠状动脉粥样硬化性心脏病患者的临床效果.中国药物经济学, 2016(2):45-47.
[8]马生胜.探讨阿托伐他汀联合曲美他嗪治疗冠状动脉粥样硬化性心脏病临床疗效.中西医结合心血管病电子杂志, 2014(6):76.